News | RIVM

Predicting who will experience symptoms after Lyme disease remains challenging

Each year, approximately 27,000 people are diagnosed with Lyme disease. For most, the symptoms disappear after treatment with antibiotics. Unfortunately, 25% of those treated have chronic symptoms, such as fatigue, concentration disorders or pain.

Number of Lyme disease diagnoses remains high

In 2021, the number of Lyme disease diagnoses with a red ring or rash– known as an erythema migrans, or EM – remained as high as in the previous survey in 2017. GPs diagnosed 25,600 patients with a red ring or rash caused by the Lyme bacteria.

Higher alert level for Ebola

There is an Ebola outbreak in several regions of Uganda that are also frequented by tourists. RIVM therefore asks medical professionals to be alert to symptoms that could indicate Ebola among people who have travelled to Uganda, and to request diagnostics to rule out or confirm Ebola.

New test for Lyme disease is not reliable

To determine whether someone has Lyme disease, doctors in the Netherlands often use antibody tests. For some time now, so-called cellular tests have been available on the market.

Verschillende commerciële laboratoria gebruiken zogeheten cellulaire testen voor Lyme. Helaas zijn niet betrouwbaar.

Ten years of Tick Radar 80,000 tick bite reports; chances of being bitten highest in Drenthe

After recording 80,000 tick bites in 10 years via Tekenradar.nl, we now know that you are most likely to be bitten by a tick in Drenthe. Quickly removing the tick halves the chance of contracting Lyme disease.

Spread of tick-borne encephalitis virus in the Netherlands

Every year about 1.5 million ticks bite someone in the Netherlands, especially between March and October. Most people will not get sick of that.

New test has no added value in Lyme disease of the central nervous system

Active Lyme disease of the central nervous system cannot be detected with an ELISpot test.

Lyme disease costs EUR 20 million annually

The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.

Guus Velders in Nature's "Ten people that mattered this year"

Researcher Dr Guus Velders of RIVM has made the Nature top-10 list of 2016. This means that, according to Nature, he was one of the 10 most influential scientists in 2016.

RIVM research basis for historic climate agreement on HFCs

Scientific research by RIVM’s Guus Velders stood partly at the basis of the HFC global climate agreement.